Amneal Pharmaceuticals, Inc. Q3 2025 Earnings Recap

Amneal Pharmaceuticals delivered a robust Q3 2025 performance, achieving revenues of $785 million and adjusted EBITDA of $160 million, marking consistent growth driven by a diversified portfolio.

Key Takeaways

• Specialty segment growth led by CREXONT for Parkinson's disease, with projected peak U.S. sales of $300 million to $500 million.
• Successful launch of the BREKIYA autoinjector, the first self-administration product for migraine, addressing a significant patient need.
• Strong momentum in GLP-1 collaboration with Metsera, with plans to establish two state-of-the-art production facilities.
• Anticipating 20 to 30 new product launches annually, with 17 already launched in 2025 and 13 more awaiting approval.
• Continued focus on complex generics and biosimilars, with 69 ANDAs pending, 64% categorized as complex products.